In the advanced field of endocrine and metabolic research, the precise modulation of growth hormone (GH) release is a subject of intense study. CJC 1295 (Without DAC), also known as Modified GRF (1-29), represents a pinnacle of peptide engineering designed for investigative purposes. This 2mg vial, provided with bacteriostatic water for reconstitution, offers researchers a highly refined tool to explore the dynamics of GH pulsatility, tissue repair, and metabolic function without the extended activity profile induced by Drug Affinity Complex (DAC) technology.
This product description provides a comprehensive, scientifically-grounded overview of CJC 1295 (Without DAC), detailing its mechanism, key research applications, distinguishing features, and proper handling protocols for the qualified research professional.
CJC 1295 is a synthetic analog of the endogenous Growth Hormone-Releasing Hormone (GHRH). The native GHRH, comprising 44 amino acids, is naturally produced by the hypothalamus and stimulates the anterior pituitary gland to secrete growth hormone in a pulsatile manner. The "Without DAC" variant, specifically, is a truncated and modified sequence encompassing the first 29 amino acids of GHRH, with key substitutions to enhance its stability and bioactivity.
Primary Structural Modifications:
Substitution of Alanine at position 2: Replacement with D-Alanine significantly reduces degradation by dipeptidyl peptidase-IV (DPP-IV) enzyme, dramatically increasing the peptide's half-life in circulation compared to the native fragment.
Other Stabilizing Modifications: Additional amino acid alterations further contribute to metabolic stability and receptor binding affinity.
Crucial Distinction: "Without DAC" vs. "With DAC"
This is the most critical differentiator for researchers. The original CJC 1295 with DAC includes a Drug Affinity Complex that binds the peptide reversibly to albumin in the bloodstream, creating a sustained-release effect with a half-life extending to several days. CJC 1295 Without DAC, as offered in this vial, lacks this complex. Consequently, it has a much shorter half-life (approximately 30 minutes), leading to a sharp, transient, and more physiological pulsatile release of Growth Hormone. This makes it an essential compound for studies aiming to mimic the body's natural GH secretion patterns.
The action of CJC 1295 (Without DAC) is elegant in its specificity:
Receptor Binding: Upon administration, the peptide binds selectively and with high affinity to the GHRH receptors (GHRH-R) located on the somatotroph cells in the anterior pituitary gland.
Signal Transduction: This binding activates intracellular cAMP and calcium-dependent signaling pathways.
GH Synthesis & Secretion: The signal cascade culminates in the increased synthesis and, most importantly, the rapid secretion of endogenous Growth Hormone into the bloodstream.
Downstream IGF-1 Production: The released GH travels to target tissues, primarily the liver, stimulating the production of Insulin-like Growth Factor-1 (IGF-1), a primary mediator of GH's anabolic and metabolic effects.
This entire process amplifies the body's own natural hormonal machinery, making it a subject of interest for research into conditions or states characterized by diminished GH pulsatility.
CJC 1295 (Without DAC) is utilized in preclinical research models to investigate a wide array of physiological processes. Its pulsatile action profile makes it particularly suited for studies on:
Muscle Tissue Physiology and Recovery: Research focuses on GH's role in promoting protein synthesis, inhibiting protein breakdown, and stimulating satellite cell activation. Studies may explore its potential in models of muscle atrophy, injury repair, and exercise-induced stress.
Metabolic Function and Body Composition: Investigators examine the peptide's influence on lipid metabolism (increased lipolysis), glucose homeostasis, and energy expenditure. Its role in modulating adipose tissue and supporting lean mass accrual is a significant area of inquiry.
Connective Tissue and Bone Health: GH and IGF-1 are crucial for collagen synthesis and bone remodeling. Research may target tendon, ligament, and skeletal integrity.
Sleep and Circadian Endocrinology: Given the natural pulsatile secretion of GH during slow-wave sleep, CJC 1295 (Without DAC) serves as a tool to study the interplay between sleep architecture, GH release, and recovery processes.
Aging Research: The well-documented decline in GH secretion with age (somatopause) is linked to changes in body composition, vitality, and recovery. Research using this peptide models interventions aimed at restoring a more youthful pulsatile GH profile.
Comparative Pharmacodynamics: It is often studied in comparison to its DAC-conjugated counterpart and other secretagogues like GHRP-6 or Ipamorelin to contrast pulsatile versus sustained GH release profiles and their distinct physiological outcomes.
This 2mg vial of CJC 1295 (Without DAC) is manufactured and supplied to meet the exacting standards required for consistent research outcomes.
High Purity Specification: ≥ 98% purity as verified by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis.
Precise Formulation: Each vial contains exactly 2mg of lyophilized (freeze-dried), sterile-filtered peptide powder.
Sterile Presentation: The peptide is housed in a sterile, tamper-evident glass vial with a rubber stopper and aluminum seal.
Included Reconstitution Solution: Each peptide vial is paired with a separate 2ml vial of USP-grade Bacteriostatic Water (0.9% Benzyl Alcohol). This sterile solvent is essential for dissolving the peptide and, due to the bacteriostatic agent, allows for multi-dose use when stored correctly post-reconstitution.
Stability: In its lyophilized state and stored at -20°C or below, the peptide remains stable for extended periods. Once reconstituted with the provided bacteriostatic water, it must be refrigerated and is typically stable for several weeks.
Intended Use: For laboratory research use only. Not for human or veterinary diagnostic, therapeutic, or consumption purposes. This product is strictly for in-vitro (cell culture) or pre-clinical animal study applications by qualified professionals in controlled laboratory settings.
Reconstitution:
Gently inject the bacteriostatic water from the supplied vial into the vial containing the lyophilized CJC 1295 powder.
Aim the stream of liquid against the glass wall to minimize forceful impact on the peptide structure.
Swirl the vial gently or roll between hands until the powder is fully dissolved. Do not shake vigorously.
Dosage Considerations (Research Models):
Research dosage is highly model-dependent and must be determined by the principal investigator based on study design. Dosages in animal models are typically calculated on a microgram-per-kilogram (μg/kg) basis. The pulsatile nature of the compound often leads to research protocols involving frequent, low-to-moderate dose administrations (e.g., once or twice daily) to simulate endogenous pulses.
Storage:
Unreconstituted (Lyophilized Powder): Store at or below -20°C in a dedicated freezer. Protect from light.
Reconstituted Solution: Store refrigerated at 2°C to 8°C in the dark. Use within a timeframe determined by laboratory sterility protocols (typically up to 30 days when reconstituted with bacteriostatic water).
Disclaimer:
This product is sold as a chemical for scientific research. It is the responsibility of the purchasing entity and the principal researcher to comply with all local, state, federal, and institutional guidelines governing the acquisition, handling, and use of bioactive peptides. This description is for informational purposes and does not constitute a medical claim or recommendation.
On all orders is set at $25.00
Protected by Bitcoin
On all huge orders